BCAX
Bicara Therapeutics·NASDAQ
--
--(--)
--
--(--)
BCAX fundamentals
Bicara Therapeutics (BCAX) expects to report earnings on Mar 30, 2026, with estimated revenue of 0 (YoY --), and EPS at -0.6722 (YoY -72.36%).
Revenue estimate / YoY
0
--
EPS estimate / YoY
-0.6722
-72.36%
Report date
Mar 30, 2026
Earnings Call
8:30 AM on Mar 30, 2026
Meeting link.EPS
Actual | -1.6 | -0.39 | -0.68 | -0.5 | -0.67 | |
Forecast | -0.41 | -0.3292 | -0.415 | -0.554 | -0.5411 | -0.6722 |
Surprise | -290.24% | -18.47% | -63.86% | +9.75% | -23.82% | 0.00% |
Revenue
Actual | 0 | 0 | 0 | 0 | 0 | -- |
Forecast | 0 | 0 | 0 | 0 | 0 | 0 |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
What guidance did Bicara Therapeutics's management provide for the next earnings period?What is Bicara Therapeutics's latest dividend and current dividend yield?What were the key takeaways from Bicara Therapeutics's earnings call?What is the revenue and EPS growth rate for Bicara Therapeutics year over year?What is the market's earnings forecast for Bicara Therapeutics next quarter?What does Bicara Therapeutics do and what are its main business segments?What factors drove the changes in Bicara Therapeutics's revenue and profit?What is Bicara Therapeutics's gross profit margin?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
